Long-term beta-blocker therapy after acute myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF ≥50%) shows no significant reduction in risk of death or recurrent MI compared to no beta-blocker use.
Discontinuation of beta-blockers within 12 months after acute coronary syndrome (ACS) in patients with LVEF ≥40% did not increase major adverse cardiovascular events (MACE), with a potential differential risk in STEMI versus NSTEMI subgroups.
Meta-analysis indicates declining mortality benefits of beta-blockers post-MI over time, particularly beyond the first year and in patients with preserved EF, suggesting possible detrimental effects with prolonged use in this population.
